Floatz logo

Tcelna

Autoimmune Diseases of the Nervous System

Opexa Therapeutics, Inc.Cell therapyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Autoimmune Diseases of the Nervous System cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Amsterdam UMC, location VUmc
Phase 3B
Cyclophosphamide
Indapta Therapeutics, INC.
Phase 1CCC
Fludarabine
Indapta Therapeutics, INC.
Phase 1CCC
MELATONIN
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Phase 1/2CCC
Ocrevus
Indapta Therapeutics, INC.
Phase 1CC
Mesna
Indapta Therapeutics, INC.
Phase 1CC
Idp-023
Indapta Therapeutics, INC.
Phase 1CC
ct103a cells
Tongji Hospital
Early Phase 1C

Same molecule, other indications

Tcelna is also rated in:

secondary progressive multiple sclerosisDormant
B
Indicative ·
57 / 100
View asset →
Disease ProgressionDormant
B
Indicative ·
57 / 100
View asset →
Brain AtrophyDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →